C-kit expression in renal oncocytomas and chromophobe renal cell carcinomas

被引:84
作者
Huo, L
Sugimura, J
Tretiakova, MS
Patton, KT
Gupta, R
Popov, B
Laskin, WB
Yeldandi, A
Teh, BT
Yang, XMJ [1 ]
机构
[1] Northwestern Univ, Northwestern Mem Hosp, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA
[2] Van Andel Res Inst, Canc Genet Lab, Grand Rapids, MI 49503 USA
[3] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA
关键词
C-kit; renal cell carcinoma; oncocytoma; angiomyolipoma;
D O I
10.1016/j.humpath.2005.01.011
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
C-kit encodes the membrane-bound tyrosine kinase KIT, whose expression has been identified in several types of human neoplasms. Recently, KIT has been reported to be a marker for chromophobe renal cell carcinoma (RCC) and renal angiomyolipoma. However, expression of this molecule has not been adequately studied in other renal tumors, particularly oncocytoma, which may morphologically resemble chromophobe RCC. In this study, we analyzed c-kit messenger RNA (mRNA) levels in 17 chromophobe RCCs and 20 renal oncocytomas obtained from complementary DNA (cDNA) microarrays. Furthermore, comprehensive immunohistochemical analysis of KIT protein using a monoclonal antibody was performed in 226 renal tumors including chromophobe RCC (n = 40), oncocytoma (n = 41), clear-cell RCC (n = 40), renal angiomyolipoma (n = 29), and papillary RCC (n = 21) on tissue microarrays (TMAs) and was compared with immunostaining results from 25 chromophobe RCCs and 30 oncocytomas using standard sections. The staining intensity was semiquantitatively graded on a 3-tier scoring system. All chromophobe RCCs and oncocytomas showed significant overexpression of c-kit mRNA. The average increase of mRNA compared with normal kidney tissue was 7.4-fold for chromophobe RCCs and 7.4-fold for oncocytomas. Immunohistochemical expression of KIT was found in most chromophobe RCCs (95% in TMAs and 96% in conventional sections) and oncocytomas (88% in TMAs and 100% in conventional sections) but was infrequently observed in renal angiomyolipomas (17%), papillary RCCs (5%), and clear-cell RCCs (3%). Furthermore, the average KIT immunoreactivity in TMAs was stronger in chromophobe RCC (1.93) and oncocytoma (2.07) than in other subtypes of renal tumors tested, including angiomyolipomas (0.17), papillary RCCs (0.05), and clear-cell RCCs (0.03). In conclusion, we found a significant elevation of c-kit mRNA by cDNA expression microarrays and overexpression of KIT protein by immunohistochemistry not only in chromophobe RCCs but also in oncocytomas. In contrast, immunohistochemical expression of KIT was not detected in most other types of renal cell tumors evaluated. The differential expression of c-kit in these renal tumors may have diagnostic and therapeutic implications. (c) 2005 Published by Elsevier Inc.
引用
收藏
页码:262 / 268
页数:7
相关论文
共 27 条
[1]   CLEAR-CELL (SUGAR) TUMOR OF THE LUNG IS A LESION STRICTLY RELATED TO ANGIOMYOLIPOMA - THE CONCEPT OF A FAMILY OF LESIONS CHARACTERIZED BY THE PRESENCE OF THE PERIVASCULAR EPITHELIOID CELLS (PEG) [J].
BONETTI, F ;
PEA, M ;
MARTIGNONI, G ;
DOGLIONI, C ;
ZAMBONI, G ;
CAPELLI, P ;
RIMONDI, P ;
ANDRION, A .
PATHOLOGY, 1994, 26 (03) :230-236
[2]  
BONSIB SM, 1993, ULTRASTRUCT PATHOL, V17, P529
[3]   C-kit expression in sarcomatoid renal cell carcinoma:: Potential therapy with imatinib [J].
Castillo, M ;
Petit, A ;
Mellado, B ;
Palacín, A ;
Alcover, JB ;
Mallofré, C .
JOURNAL OF UROLOGY, 2004, 171 (06) :2176-2180
[4]   Changing concepts in the management of renal oncocytoma [J].
Chao, DH ;
Zisman, A ;
Pantuck, AJ ;
Freedland, SJ ;
Said, JW ;
Belldegrun, AS .
UROLOGY, 2002, 59 (05) :635-642
[5]   Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors [J].
Demetri, GD ;
von Mehren, M ;
Blanke, CD ;
Van den Abbeele, AD ;
Eisenberg, B ;
Roberts, PJ ;
Heinrich, MC ;
Tuveson, DA ;
Singer, S ;
Janicek, M ;
Fletcher, JA ;
Silverman, SG ;
Silberman, SL ;
Capdeville, R ;
Kiese, B ;
Peng, B ;
Dimitrijevic, S ;
Druker, BJ ;
Corless, C ;
Fletcher, CDM ;
Joensuu, H .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :472-480
[6]   Gastrointestinal stromal tumors: Biology and treatment [J].
Duffaud, F ;
Blay, JY .
ONCOLOGY, 2003, 65 (03) :187-197
[7]   Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations [J].
Heinrich, MC ;
Rubin, BP ;
Longley, BJ ;
Fletcher, JA .
HUMAN PATHOLOGY, 2002, 33 (05) :484-495
[8]   Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors [J].
Hirota, S ;
Isozaki, K ;
Moriyama, Y ;
Hashimoto, K ;
Nishida, T ;
Ishiguro, S ;
Kawano, K ;
Hanada, M ;
Kurata, A ;
Takeda, M ;
Tunio, GM ;
Matsuzawa, Y ;
Kanakura, Y ;
Shinomura, Y ;
Kitamura, Y .
SCIENCE, 1998, 279 (5350) :577-580
[9]   DISTURBED INTESTINAL MOVEMENT, BILE REFLUX TO THE STOMACH, AND DEFICIENCY OF C-KIT-EXPRESSING CELLS IN WS/WS MUTANT RATS [J].
ISOZAKI, K ;
HIROTA, S ;
NAKAMA, A ;
MIYAGAWA, JI ;
SHINOMURA, Y ;
XU, ZD ;
NOMURA, S ;
KITAMURA, Y .
GASTROENTEROLOGY, 1995, 109 (02) :456-464
[10]  
KITAMURA Y, 1979, BLOOD, V53, P492